Terazosin
- Generic Name
- Terazosin
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25N5O4
- CAS Number
- 63590-64-7
- Unique Ingredient Identifier
- 8L5014XET7
Overview
Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate.
Background
Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate.
Indication
Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension.
Associated Conditions
- Benign Prostatic Hyperplasia (BPH)
- Hypertension
- Ureteral Calculus
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.